AG0302-COVID‑19
Jump to navigation
Jump to search
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | DNA |
| Clinical data | |
| Routes of administration | Intramuscular |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
AG0302-COVID‑19 is a COVID-19 vaccine candidate developed by AnGes Inc.[1][2][3]
This candidate followed a previous one called AG0301-COVID‑19.[4]
References[edit]
- ^ "Study of COVID-19 DNA Vaccine (AG0302-COVID19)". clinicaltrials.gov. United States National Library of Medicine. Retrieved 11 March 2021.
- ^ "The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19". ClinicalTrials.gov. United States National Library of Medicine. NCT04659239. Retrieved 10 March 2021.
- ^ "Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19)". clinicaltrials.gov. United States National Library of Medicine. Retrieved 11 March 2021.
- ^ "Study of COVID-19 DNA Vaccine (AG0301-COVID19)". ClinicalTrials.gov. United States National Library of Medicine. 9 July 2020. NCT04463472. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
External links[edit]
 |
Scholia has a profile for AG0302-COVID‑19 (Q106514993). |
.png){kind=small} | This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |